title: Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS.
abstract: A 25-year-old woman with AIDS was submitted to HLA-identical allogeneic BMT after cytoablation with busulphan and cyclophosphamide and combined anti-HIV-1 therapy with zidovudine, IFN-alpha 2 and anti-HIV-1-specific T cell clones. Marrow engraftment occurred after 18 days and tests for HIV-1 were negative after 30 days but the hematologic reconstitution of the patient was poor. A second BM infusion from the same donor was ineffective and treatment with GM-CSF only induced a transient increase of the blood cell count, suggesting iatrogenic damage to the BM microenvironment. The development of ARDS led to the death of the patient 10 months after transplantation. Post-mortem investigation did not reveal any active infections and PCR on autopsy tissues was negative for HIV-1.
authors.affiliation: Istituto di Clinica Medica, Università di Cagliari, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Contu
authors.forename: G
authors.initials: G
authors.lastname: La Nasa
authors.forename: M
authors.initials: M
authors.lastname: Arras
authors.forename: A
authors.initials: A
authors.lastname: Pizzati
authors.forename: A
authors.initials: A
authors.lastname: Vacca
authors.forename: C
authors.initials: C
authors.lastname: Carcassi
authors.forename: A
authors.initials: A
authors.lastname: Ledda
authors.forename: R
authors.initials: R
authors.lastname: Boero
authors.forename: S
authors.initials: S
authors.lastname: Orrù
authors.forename: A
authors.initials: A
authors.lastname: Pintus
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000601:surgery* / Q000628:therapy; D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology / Q000379:methods; D002066:Busulfan / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D011994:Recombinant Proteins; D012128:Respiratory Distress Syndrome / Q000209:etiology; D014184:Transplantation, Homologous; D015215:Zidovudine / Q000008:administration & dosage
chemical_list: D000961:Antilymphocyte Serum; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015215:Zidovudine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D002066:Busulfan